GC Biopharma Corp - Company Profile
Powered by 
All the sales intelligence you need on GC Biopharma Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how GC Biopharma Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with GC Biopharma Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
GC Biopharma Corp (GC Biopharma), formerly GC Pharma, provides plasma protein therapeutics and vaccines. The company develops, manufactures, and markets plasma-derived products, including albumin, immunoglobulin, and antithrombin. It also produces vaccines to prevent infectious diseases and a portfolio of prescription medicines addressing cardiovascular, respiratory, central nervous system, gastrointestinal, immunology, musculoskeletal, genetic, metabolic, and hematological disorders. In the consumer health segment, GC Biopharma offers over-the-counter products such as anti-inflammatory medicines, anti-allergy treatments, and other self-care options. The company’s research and development activities focus on advancing new therapies for cancer, tuberculosis, and Hunter syndrome, as well as additional unmet medical needs. GC Biopharma is headquartered Yongin, Gyeonggi-do, South Korea.
GC Biopharma Corp premium industry data and analytics
Products and Services
| Products |
|---|
| Prescription Drugs |
| Over-The-Counter Drugs |
| Quasi Drugs |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In August, the company received approval from India's Central Drugs Standard Control Organization and Taiwan's Food and Drug Administration for its Hunter syndrome treatment Hunterase IV in India and Taiwan. |
| 2026 | Contracts/Agreements | In May, the company signed an MoU with Merck Life Science to deepen collaboration in biopharma development and GMP manufacturing. |
| 2026 | Regulatory Approval | In March, the company secured approval from the Ministry of Public Health and Social Assistance (Ministerio de Salud Pública y Asistencia Social) of Guatemala for varicella vaccine, BARYCELA Inj. |
Competitor Comparison
| Key Parameters | GC Biopharma Corp | Yuhan Corp | Huons Global Co Ltd | Suheung Capsule Co Ltd | Jeil Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Yongin-si | Seoul | Seongnam | Cheongju | Seoul |
| State/Province | - | - | - | - | Seoul |
| No. of Employees | 2,355 | 1,594 | 541 | 727 | 978 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Il-sup Huh | Chairman; Chief Executive Officer | Executive Board | 2009 | 72 |
| Heo Eun-cheol | Chief Executive Officer; Director | Executive Board | - | 54 |
| Jeong Jae-wook | Director; Head - R&D Division | Executive Board | 2022 | 62 |
| Shin Woong | Director; Head - Quality Management | Executive Board | 2021 | 54 |
| Namkoong Hyun | Head - Marketing | Senior Management | 2022 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer